AIM ImmunoTech In…
USUSDAIM ImmunoTech Inc (LSE:0A4Y) — Biotechnology: Biological Products (No Diagnostic Substances). Numero di borse in cui sono quotate le azioni della società: 2. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- aimimmuno.com
- Relazioni con gli Investitori
- aimimmuno.com/investors/
- Settore
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sede Centrale
- OCALA, United States
- Amministratore Delegato
- Thomas K. Equels
- Dipendenti
- 19
- Azioni in Circolazione
- 30.44 Mln al 2026-08-07
- Flottante
- 27.64 Mln
- Capitalizzazione di Mercato
- 7.18 Mln USD
- Insider
- 0.51%
- Investitori Istituzionali
- 2.88%
- Settore (SIC)
- Biological Products, (No Diagnostic Substances)
- FCF
- —
- Debito
- 3.62 Mln USDliquidità netta
- Utili e FCF — per i 12 mesi a 30.06.2026 (l'ultimo rapporto dell'azienda).
- NAV
Descrizione
AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection (Interferon alfa), a purified, natural-source, glycosylated, multi-species alpha interferon product for the treatment of genital warts. It is also developing Ampligen for potential treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| KELLNER TED D (Director) | ≈4.88% | 3.72 Mln | 2025-04-11 |
| Jane Street Group, LLC | 1.06% | 807 885 | 2026-06-30 |
| MITCHELL WILLIAM M (Dire… | ≈0.69% | 522 103 | 2025-04-11 |
| RODINO PETER W III (Chie… | ≈0.53% | 401 762 | 2025-04-04 |
| APPELROUTH STEWART L. (D… | ≈0.51% | 388 729 | 2024-12-31 |
| BRYAN NANCY K (Director) | ≈0.38% | 291 882 | 2025-03-14 |
| Virtu Financial LLC | 0.16% | 124 269 | 2026-06-30 |
| EQUELS THOMAS K (Officer… | ≈0.13% | 102 822 | 2026-09-16 |
| Morgan Stanley | 0.07% | 50 864 | 2026-06-30 |
| Geode Capital Management… | 0.06% | 46 003 | 2026-06-30 |
| Fidelity Concord Street… | 0.06% | 44 084 | 2026-07-31 |
| Goldman Sachs Group Inc | 0.04% | 32 444 | 2026-06-30 |
| UBS Group AG | 0.04% | 28 931 | 2026-06-30 |
| CHEMEROW DAVID I (Direct… | ≈0.04% | 28 441 | 2026-03-12 |
| Susquehanna Internationa… | 0.03% | 21 859 | 2026-06-30 |
| Vanguard Fiduciary Trust… | 0.02% | 17 519 | 2026-06-30 |
| Ground Swell Capital, LL… | 0.02% | 12 222 | 2026-06-30 |
| Tower Research Capital L… | 0.01% | 4 668 | 2026-06-30 |
| Fidelity Concord Street… | 0% | 682 | 2026-07-31 |
Accedi con Google